Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 6/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.45 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.45 |
| ▸ | KDM5A | P29375 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5510433 | 0.90 | ABL1 (0.54) | CETPCHRM2CHRM1CHRM3MAPK14 | |
| SCHEMBL10916459 | 0.85 | CETP (0.42) | CETPCHRM2CHRM1CHRM3MAPK14 | |
| SCHEMBL1047407 | 0.85 | CYP4F2 (0.56) | CETPCHRM2CHRM1CHRM3MAPK14 | |
| SCHEMBL5009648 | 0.84 | DAO (0.55) | CETPCHRM2CHRM1CHRM3MAPK14 | |
| SCHEMBL5750323 | 0.84 | CETP (0.51) | CETP | |
| SCHEMBL19062249 | 0.82 | CETP (0.53) | CETPCHRM2CHRM1CHRM3MAPK14 | |
| SCHEMBL178310 | 0.82 | CHRM2 (0.55) | CETPCHRM2CHRM1CHRM3MAPK14 | |
| SCHEMBL79435 | 0.82 | CHRM2 (0.52) | CETPCHRM2CHRM1CHRM3MAPK14 | |
| SCHEMBL31374889 | 0.81 | LTA4H (0.58) | CETPMAPK14 | |
| SCHEMBL447002 | 0.81 | CETP (0.51) | CETPCHRM2CHRM1CHRM3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 524 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112341546-B | Preparation method of fluorinated biomass membrane material | 北京化工大学 | 2022-07-05 | — | — | CN | claimed |
| CN-112341546-A | Preparation method of fluorinated biomass membrane material | 北京化工大学 | 2021-02-09 | — | — | CN | claimed |
| EP-1115693-B9 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO CO (US) | 2007-12-19 | — | — | EP | claimed |
| EP-1115693-B1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO CO (US) | 2007-05-02 | — | — | EP | claimed |
| US-7122536-B2 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | PFIZER INC. (US) | 2006-10-17 | — | — | US | claimed |
| US-7015223-B1 | Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2006-03-21 | — | — | US | claimed |
| US-7015230-B1 | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2006-03-21 | — | — | US | claimed |
| EP-1589000-A2 | (R)-Chiral halogenated 1-substitutedamino-(N+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity | Monsanto Company (US) | 2005-10-26 | — | — | EP | claimed |
| US-20050165021-A1 | Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-07-28 | — | — | US | claimed |
| US-20050153965-A1 | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-07-14 | — | — | US | claimed |
| WO-2001077079-A2 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-10-18 | — | — | WO | claimed |
| WO-2001068605-A1 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED BENZENES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-09-20 | — | — | WO | claimed |
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2001-08-30 | — | — | US | claimed |
| EP-1115695-A1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(N+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| EP-1115694-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC (TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018724-A1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| WO-2000018723-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| US-4423243-A | Process for the preparation of 2,2-dimethyl-3-vinyl-cyclopropanecarboxylic acids and esters | BAYER AKTIENGESELLSCHAFT (DE) | 1983-12-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165021-A1 | Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, F2 | CETP 1626/4885CHRM2 4764/4885CHRM1 4564/4885 |
| US-20010018446-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | CETP 1/4885CHRM2 4067/4885CHRM1 3159/4885 |
| US-20050153965-A1 | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade | TFPI, F2, PLAT | CETP 1179/4885CHRM2 4829/4885CHRM1 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.